Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade

Cancer Immunology Research - Tập 5 Số 1 - Trang 52-60 - 2017
Shane A. Curran1, Justin A. Shyer1, Erin T. St. Angelo1, Lillian R. Talbot1, Sneh Sharma1, David J. Chung1,2,3,4,5, Glenn Heller6, Katharine C. Hsu1,2,4, Brian C. Betts1,2, James W. Young1,2,4,5
11Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.
22Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, MSKCC, New York, New York.
33Myeloma Service, Division of Hematologic Oncology, Department of Medicine, MSKCC, New York, New York.
44Weill Cornell Medical College, New York, New York.
55The Rockefeller University, New York, New York.
66Biostatistics Service, Department of Biostatistics and Epidemiology, New York, New York.

Tóm tắt

AbstractJanus kinase (JAK) inhibitors have achieved positive responses in myeloproliferative neoplasms, but at the expense of decreased natural killer (NK) cell numbers and compromised function. Selective JAK2 inhibition may also have a role in preventing and treating graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Although JAK inhibitors can impair monocyte-derived dendritic cell (moDC) activation and function and suppress effector T-cell responses, the effects on NK cells and the relevant mechanisms remain undefined. Using common γc cytokines and distinct human dendritic cell (DC) subtypes, we compared the effects of a JAK2-specific (TG101348) with a less selective JAK1/2 (ruxolitinib) inhibitor on NK-cell activation and function. Ruxolitinib treatment completely blocked IL2, IL15, and DC-mediated STAT5 phosphorylation, along with the capacity of NK cells to secrete IFNγ or lyse NK cell–sensitive targets. Only NK-cell proliferation stimulated by moDCs resisted ruxolitinib treatment. In contrast, TG101348 treatment of stimulated NK cells resulted in far less functional compromise. TG101348 completely inhibited only soluble IL15-mediated STAT5 phosphorylation, which Langerhans-type DCs (LCs), presenting membrane-bound IL15 in trans, could salvage. These results demonstrate that ruxolitinib's nonselective inhibition of JAK1/2 results in profound NK-cell dysfunction by blocking downstream pSTAT5, hence providing a persuasive rationale for the development of selective JAK2 inhibitors for immunotherapeutic applications. Cancer Immunol Res; 5(1); 52–60. ©2016 AACR.

Từ khóa


Tài liệu tham khảo

Henden, 2015, Cytokines in graft-versus-host disease, J Immunol, 194, 4604, 10.4049/jimmunol.1500117

Wernig, 2008, Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera, Cancer Cell, 13, 311, 10.1016/j.ccr.2008.02.009

Betts, 2011, Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells, yet preserves immunity to recall antigen, Blood, 118, 5330, 10.1182/blood-2011-06-363408

Ghoreschi, 2009, Janus kinases in immune cell signaling, Immunol Rev, 228, 273, 10.1111/j.1600-065X.2008.00754.x

Pardanani, 2015, Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial, JAMA Oncol, 1, 643, 10.1001/jamaoncol.2015.1590

Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440

Lundqvist, 2007, Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors, Blood, 109, 3603, 10.1182/blood-2006-05-024315

Yu, 2009, Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation, Blood, 113, 3875, 10.1182/blood-2008-09-177055

Zeiser, 2015, Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey, Leukemia, 29, 2062, 10.1038/leu.2015.212

Quintas-Cardama, 2010, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms, Blood, 115, 3109, 10.1182/blood-2009-04-214957

Waldmann, 2006, The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design, Nat Rev Immunol, 6, 595, 10.1038/nri1901

O'Shea, 2012, JAK and STAT signaling molecules in immunoregulation and immune-mediated disease, Immun, 36, 542, 10.1016/j.immuni.2012.03.014

Heine, 2013, The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo, Blood, 122, 1192, 10.1182/blood-2013-03-484642

Caocci, 2014, Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis, Leukemia, 28, 225, 10.1038/leu.2013.235

Schonberg, 2015, JAK inhibition impairs NK cell function in myeloproliferative neoplasms, Cancer Res, 75, 2187, 10.1158/0008-5472.CAN-14-3198

Munz, 2005, Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells, Blood, 105, 266, 10.1182/blood-2004-06-2492

Curran, 2014, Phenotypic and functional activation of hyporesponsive KIRnegNKG2Aneg human NK-cell precursors requires IL12p70 provided by Poly(I:C)-matured monocyte-derived dendritic cells, Cancer Immunol Res, 2, 1000, 10.1158/2326-6066.CIR-14-0054-T

Shilling, 2010, Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans, Drug Metab Dispos, 38, 2023, 10.1124/dmd.110.033787

Ratzinger, 2004, Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells, J Immunol, 173, 2780, 10.4049/jimmunol.173.4.2780

Romano, 2012, Human Langerhans cells use an IL-15R-alpha/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1, Blood, 119, 5182, 10.1182/blood-2011-09-382200

Pillet, 2009, A programmed switch from IL-15- to IL-2-dependent activation in human NK cells, J Immunol, 182, 6267, 10.4049/jimmunol.0801933

Wang, 2000, Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4, Blood, 95, 3183, 10.1182/blood.V95.10.3183

Cho, 1996, Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation, J Immunol, 157, 4781, 10.4049/jimmunol.157.11.4781

Alter, 2004, CD107a as a functional marker for the identification of natural killer cell activity, J Immunol Methods, 294, 15, 10.1016/j.jim.2004.08.008

Waldmann, 2001, Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy, Immun, 14, 105

Barreira da Silva, 2011, Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals, Cell Mol Life Sci, 68, 3505, 10.1007/s00018-011-0801-8

Nguyen, 2002, Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection, J Immunol, 169, 4279, 10.4049/jimmunol.169.8.4279

Romee, 2012, Cytokine activation induces human memory-like NK cells, Blood, 120, 4751, 10.1182/blood-2012-04-419283

Yu, 1996, Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-alpha, J Immunol, 157, 126, 10.4049/jimmunol.157.1.126

Zeiser, 2007, Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease, Blood, 109, 2225, 10.1182/blood-2006-07-038455

Shimoda, 2002, Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice, Blood, 99, 2094, 10.1182/blood.V99.6.2094

Rolle, 2014, IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion, J Clin Invest, 124, 5305, 10.1172/JCI77440

Cichocki, 2016, CD56(dim)CD57(+)NKG2C(+) NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT, Leukemia, 30, 456, 10.1038/leu.2015.260

Wang, 1999, IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells, J Immunol, 162, 299, 10.4049/jimmunol.162.1.299

Olson, 2010, NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects, Blood, 115, 4293, 10.1182/blood-2009-05-222190

Thông tin
Thông tin xuất bản

Cancer Immunology Research

Tập 5 Số 1

52-60

Thông tin tác giả